Mersana Therapeutics
Yahoo Finance • 10 months ago
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story
Yahoo Finance • last year
Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results
Mersana Therapeutics Inc (NASDAQ:MRSN) released its Q3 2023 financial results on November 7, 2023. The company reported a net loss of $41.6 million for the quarter, compared to a net loss of $59.8 million in Q3 2022. Collaboration revenue... Full story
Yahoo Finance • last year
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADCCapital resources exp... Full story
Yahoo Finance • last year
Mersana Therapeutics Announces Changes in Leadership
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chie... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. (“Mersana” or the “Company”) (NASDAQ: MRSN). Such investors are advised to contact Robert S. Willoug... Full story
Yahoo Finance • last year
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancer... Full story
Yahoo Finance • last year
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Mersana Therapeutics (MRSN) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
SAN FRANCISCO, July 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ: MRSN) investors who suffered substantial losses to submit your losses now. Visit:www.hbsslaw.com/investor-fraud/mrsn Contact An At... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
NEW YORK, July 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. (“Mersana” or the “Company”) (NASDAQ: MRSN). Such investors are advised to contact Robert S. Willoug... Full story
Yahoo Finance • last year
Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc. (NASDAQ: MRSN) securities. Click Here To Join I... Full story
Yahoo Finance • last year
INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc. (Nasdaq: MRSN) securities. Click Here To Join I... Full story
Yahoo Finance • last year
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cance... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023Advanced enrollment in Phase 3 UP-NEXT clinical trial of UpRi and Phase 1 clinical trial of X... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancer... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancer... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting canc... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Provides Statement About SVB
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting canc... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participa... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatin Initiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate, XMT-2056 Entered new research collaboratio... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cance... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cance... Full story
